Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Cut by F M Investments LLC

F M Investments LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,453 shares of the biopharmaceutical company’s stock after selling 255 shares during the period. F M Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $6,784,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Farther Finance Advisors LLC grew its position in Regeneron Pharmaceuticals by 7.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 724 shares of the biopharmaceutical company’s stock valued at $761,000 after buying an additional 53 shares in the last quarter. Americana Partners LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $330,000. Focus Financial Network Inc. grew its position in Regeneron Pharmaceuticals by 7.4% in the 3rd quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock valued at $566,000 after buying an additional 37 shares in the last quarter. LCM Capital Management Inc grew its position in Regeneron Pharmaceuticals by 4.6% in the 3rd quarter. LCM Capital Management Inc now owns 543 shares of the biopharmaceutical company’s stock valued at $571,000 after buying an additional 24 shares in the last quarter. Finally, Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $843.60 on Friday. The company has a 50 day simple moving average of $1,058.43 and a 200-day simple moving average of $1,039.88. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.99 and a quick ratio of 4.62. The firm has a market capitalization of $93.00 billion, a price-to-earnings ratio of 20.88, a price-to-earnings-growth ratio of 2.88 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $783.57 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the prior year, the company posted $8.79 earnings per share. The firm’s revenue was up 12.3% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Barclays cut their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $1,090.24.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.